Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Galectin Therapeutics Inc. (GALT) had Debt to Equity Ratio of -1.06 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-30.97M |
|
-- |
|
-- |
|
$20.09M |
|
$-20.09M |
|
$-10.75M |
|
$-30.84M |
|
$-30.84M |
|
$-30.84M |
|
$-30.84M |
|
$-30.84M |
|
$-30.84M |
|
$-20.09M |
|
$-20.03M |
|
63.90M |
|
63.90M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$19.44M |
|
-- |
|
$0.10M |
|
$19.53M |
|
$8.03M |
|
$133.74M |
|
$137.70M |
|
$145.73M |
|
$-128.41M |
|
$-126.19M |
|
$-126.19M |
|
65.20M |
|
| Cash Flow Statement Financials | |
$-23.88M |
|
-- |
|
$26.48M |
|
$15.12M |
|
$17.72M |
|
$2.60M |
|
$1.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.42 |
|
-- |
|
-- |
|
17.74 |
|
|
Debt to Equity Ratio |
-1.06 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
24.01% |
|
24.44% |
|
-157.87% |
|
-408.97% |
|
$-1.94 |
|
$-0.37 |
|
$-0.37 |
|